News

Dr Polisky replaces Steven Quay, chief scientific officer, chairman of the board of directors and chairman of the scientific advisory board, who will be leaving the company on

These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and cognitive

LoSeasonique is the first lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy, said Barr. Under the LoSeasonique extended-cycle regimen, women take combination tablets containing 0.10mg levonorgestrel/0.02mg

Under the terms of the license agreement, BioWa grants KaloBios non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of

According to the agreement, Laureate will produce Tolera’s TOL101 monoclonal antibody under current good manufacturing practice (cGMP) conditions to be used in clinical trials. John Puisis, president and

Under the terms of the agreement, Exiqon obtains from Roche a non-exclusive license to use SYBR Green I in real time polymerase chain reaction (PCR). SYBR Green provides

Ikonisys said that oncoFISH her2 is a fully automated microscopy application for the determination of HER2 status in human breast cancer specimens processed with Abbott’s PathVysion HER2 DNA

Together, these licenses from the regulatory bodies ensure this facility is ready to support the supply of Bayer’s Kogenate FS/ Kogenate Bayer (antihemophilic factor [recombinant]) line of products

The Phase II trial compared the efficacy and safety of five days of therapy with either 200mg intravenous (IV) peramivir per day, 400mg IV peramivir per day or